What is in the KLOW peptide blend?

KLOW refers to KPV, BPC-157, TB-500 and GHK-Cu combined. It is an informal name, so the exact contents can differ between sources.

Has KLOW been tested in humans?

No. There are no published studies of the four-peptide combination. Each part has its own limited research, mostly in cells and animals.

What does the K in KLOW stand for?

The K stands for KPV, a three-amino-acid fragment of alpha-MSH that is added to the three peptides in the GLOW blend.

Is KLOW better than GLOW?

There is no research comparing them. Neither blend has been studied as a combination.

KLOW Peptide Blend (KPV, BPC-157, TB-500, GHK-Cu): Research, Safety

The peptides in this stack

KPV BPC-157 TB-500 GHK-Cu

What is KLOW?

KLOW is a marketing name for a mix of four separate peptides. KPV is a three-amino-acid peptide, lysine, proline and valine, matching the end of alpha-MSH. BPC-157 is a 15-amino-acid synthetic peptide based on part of a protein reported in human gastric juice. TB-500 is a synthetic peptide modeled on thymosin beta-4, usually a short actin-binding fragment. GHK-Cu is a three-amino-acid peptide found in human plasma, bound to copper.

The K in the name stands for KPV, added to the three peptides of the GLOW blend. None of the four is an approved medicine, and each was developed and studied separately by different research groups. Because KLOW is an informal name, the forms and proportions of each peptide can differ between sources.

How does KLOW work?

The reasoning for the blend is that each part seems to act on a different step of repair in lab and animal studies. KPV reduced NF-kappa B activity and inflammatory signals in cell studies. BPC-157 has been linked to blood vessel growth through the VEGF pathway. Thymosin beta-4, the basis for TB-500, binds actin and has been linked to cell migration toward injured tissue. GHK-Cu delivers copper and increased collagen production in cell studies.

Putting an anti-inflammatory piece alongside repair-focused pieces is a logical idea on paper. It is still a hypothesis. No published research has tested what these four do together, whether they interact, or how the mix affects safety. More ingredients also mean more ways for effects and side effects to overlap.

What has research looked at?

KPV: Cell studies and mouse models of colitis reported less gut inflammation. No published human trials exist.
BPC-157: Rat studies reported better healing of tendons, ligaments, muscle and gut lining. Human data are limited to a few small, uncontrolled reports.
TB-500 and thymosin beta-4: Full-length thymosin beta-4 was studied in animals for wounds and heart injury, and in small human trials for skin ulcers and eye conditions, with mixed results. The TB-500 fragment itself has very little research.
GHK-Cu: Lab and animal studies reported more collagen and faster wound closure, and small cosmetic studies of creams reported modest skin improvements.
The combination: There are no published animal or human studies of these four peptides given together.

So the case for KLOW rests on four separate, mostly preclinical bodies of research. Only GHK-Cu applied to the skin and full-length thymosin beta-4 have meaningful human trial data, and neither was tested as part of a blend. Adding more ingredients does not add evidence for the combination, and it adds more unknowns.

KLOW vs GLOW

GLOW combines BPC-157, TB-500 and GHK-Cu. KLOW adds KPV. The addition is meant to bring an anti-inflammatory element, based on cell and mouse research on KPV and gut inflammation. Neither blend has been studied as a combination, so there is no research showing one does more than the other, or more than any single part alone.

Side effects and cautions

No safety studies exist for the four-peptide blend. Each part has limited or no human safety data, apart from GHK-Cu applied to the skin. People often report stinging or burning where blends containing GHK-Cu were injected, along with redness, nausea, digestive upset, headache or tiredness, but these reports are anecdotal. Anyone with health questions should talk to a qualified clinician.

Cancer history: BPC-157, thymosin beta-4 and GHK-Cu have been linked to blood vessel growth in lab or animal studies. That is a theoretical concern for people with current or past cancer.
Immune effects: KPV is studied for dampening inflammatory signals, and how that affects fighting infection in people is unknown.
Copper: GHK-Cu adds copper, an extra unknown for people with conditions affecting copper handling, such as Wilson disease.
Unknown interactions: Four compounds together can behave differently than each does alone, and no study has looked.
Product content: Premixed blends may not match their labels in amount or purity.
Pregnancy and breastfeeding: There are no safety data for any of the four.